Mentari Therapeutics, Inc. (MTRI)
| Market Cap | 8.24M +126.0% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 549.37K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,044 |
| Open | 14.35 |
| Previous Close | 16.00 |
| Day's Range | 14.30 - 15.55 |
| 52-Week Range | 5.75 - 23.30 |
| Beta | 0.99 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About MTRI
Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company’s products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways. The company was incorporated in 2025 and is based in Sacramento, California.
News
Mentari Therapeutics to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Mentari Therapeutics, Inc. (Nasdaq: MTRI), a clinical-stage biotechnology company developing therapies for migraine prevention, today announced that m...
InMed Pharmaceuticals Completes Closing of Merger with Mentari Therapeutics
Shares expected to trade on Nasdaq under the ticker symbol "MTRI" commencing November 9, 2026 VANCOUVER, BC, Nov. 6, 2026 /PRNewswire/ -- InMed Pharmaceuticals Inc. (which has changed its name to Ment...
InMed Announces Expected Closing of Merger and Commencement of Trading on Nasdaq Under the Name "Mentari Therapeutics, Inc." and Ticker Symbol "MTRI"
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (now Mentari Therapeutics, Inc.) (the "Company"), a pharmaceutical company focused on develo...
InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (now Mentari Therapeutics, Inc.) (the "Company"), a pharmaceutical company focused on develo...
InMed Reports First Quarter Fiscal 2027 Financial Results and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - November 3, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pro...
InMed Announces Share Consolidation in Connection with Proposed Merger
Vancouver, British Columbia--(Newsfile Corp. - November 2, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pro...
InMed Announces CVR Distribution Record Date in Connection with Proposed Merger
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pro...
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of p...
InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of pr...
Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline
WALTHAM, Mass., July 22, 2026 /PRNewswire/ -- Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a $200 millio...
InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4
Vancouver, British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered in...